ArticleFrontiers in medicine2025
Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery embolization.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- New insights on Bronchial Artery Embolization (BAE) for hemoptysis: a systematic review.BMC pulmonary medicine · 2025Pooled it
- Bronchiectasis morphology and hemoptysis recurrence after bronchial artery embolization: a cohort study using inverse probability of treatment weighting.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemoptysis is a life-threatening manifestation frequently observed in patients with cystic bronchiectasis (CB), a radiologically defined subtype of bronchiectasis. Bronchial artery embolization (BAE) is widely employed as an effective interventional therapy for controlling hemoptysis. Despite its clinical utility, the risk of recurrence remains high, particularly in patients with CB. Currently, no reliable predictive model specifically targeting CB-related hemoptysis recurrence following BAE has been established, highlighting the need for a tailored prognostic tool in this population. Objective: This study aimed to develop and validate a model to predict the recurrence of hemoptysis in CB patients following BAE, enabling individualized clinical management and prevention strategies. Methods: A retrospective study was conducted on 111 CB patients who underwent BAE between January 2015 and June 2020. Clinical, radiological, and laboratory data were collected for analysis. Least absolute shrinkage and selection operator (LASSO) regression was applied to identify relevant predictive variables, followed by multivariable Cox proportional hazards regression to determine independent prognostic factors. Based on these predictors, a nomogram was constructed. Its performance was assessed using the concordance index (C-index), receiver operating characteristic (ROC) curves, area under the curve (AUC), calibration plots, and decision curve analysis (DCA). Results: Five independent predictors were identified: history of hemoptysis (HR = 3.42, 95% CI: 1.64-7.12, Conclusion: The nomogram is a reliable tool for predicting hemoptysis recurrence in CB patients after BAE. It facilitates early identification of high-risk patients, enabling timely, targeted interventions and improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.